Alterations in the coagulation markers did not show differences with the severity of COVID‐19 in Peruvian patients: A cross‐sectional single‐center study

Background and Aims COVID‐19 is a pandemic disease that can lead to altered lung function, systemic inflammatory events, and altered coagulation. During severe stages of the disease, changes in coagulation homeostasis increase, leading to thrombosis, and increased risk of death. In this cross‐sectio...

Full description

Saved in:
Bibliographic Details
Published in:Health science reports 2023-03, Vol.6 (3), p.e1105-n/a
Main Authors: Moya‐Salazar, Jeel, Cóndor, Liliana Y., Zuñiga, Nahomi, Jaime‐Quispe, Alexis, Moya‐Salazar, Belén, Chicoma‐Flores, Karina, Cañari, Betsy, Contreras‐Pulache, Hans
Format: Article
Language:English
Subjects:
Age groups
Antigens
Blood platelets
coagulation
Consciousness
COVID-19
D dimer
Data analysis
Data collection
fibrinogen
Hospitals
Infections
Intensive care
Original Research
Oxygen saturation
Pneumonia
prothrombin time
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims COVID‐19 is a pandemic disease that can lead to altered lung function, systemic inflammatory events, and altered coagulation. During severe stages of the disease, changes in coagulation homeostasis increase, leading to thrombosis, and increased risk of death. In this cross‐sectional study, we aimed to assess coagulation markers by COVID‐19 severity in Peruvian adults. Methods During the second wave of infections, we included 186 adults diagnosed with COVID‐19 (mean age 53.3 ± 16.3 years). Patients were divided into mild, moderate, and severe stages of COVID‐19, and coagulation markers included prothrombin time (PT), activated partial prothrombin time (aPTT), fibrinogen, d‐dimer, and platelet count. Results Of the total, 120 (64.5%) were males and 39 (21%) were in the intensive care unit. We determine 104 (55.9%), 43 (24.7%), and 36 (19.4%) patients in mild, moderate, and severe stages of COVID‐19, respectively. In the severe stage of COVID‐19, patients had an average concentration of PT, aPTT, fibrinogen, d‐dimer, and platelets of 13.2 ± 0.9 s, 28.9 ± 4.3 s, 679.4 ± 185.1 mg/dL, 1.9 ± 3.1 µg/mL, and 272.8 ± 88.9 cel/10 mm,3 respectively. We found no differences in the concentration of each marker according to severity (p 
ISSN:2398-8835
2398-8835
DOI:10.1002/hsr2.1105